NIKKEI 225
28,257.25 -76.27 (-0.27%) HANG SENG
24,112.78 -105.25 (-0.43%) CRUDE OIL
86.82 +1.39 (+1.63%) GOLD FUTURES
1,814.20 +1.80 (+0.10%) DOW
35,368.47 -543.34 (-1.51%) BTC-GBP
31,164.62 -32.97 (-0.11%)
AstraZeneca PLC (AZN.L)
| Previous close | 8,770.00 |
| Open | 8,747.00 |
| Bid | 8,723.00 x 0 |
| Ask | 8,726.00 x 0 |
| Day's range | 8,631.00 - 8,766.00 |
| 52-week range | 6,499.80 - 9,523.00 |
| Volume | |
| Avg. volume | 1,947,702 |
| Market cap | 135.216B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 108.68 |
| EPS (TTM) | 80.30 |
| Earnings date | 09 Feb 2022 - 14 Feb 2022 |
| Forward dividend & yield | 2.02 (2.39%) |
| Ex-dividend date | 12 Aug 2021 |
| 1y target est | 98.40 |
- Editor's pickYahoo Finance Video
Omicron: Why a fourth dose of coronavirus vaccines may not be 'absolutely necessary,' doctor says
Dr. Robert G. Lahita MD, PhD, Director of the Institute for Autoimmune and Rheumatic Disease at Saint Joseph Health and author of Immunity Strong, joins Yahoo Finance Live to discuss the latest information on COVID-19 booster vaccinations, transmissibility, and the pressures felt by hospitals in remote regions.
- Business Wire
IMFINZI® (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years
WILMINGTON, Del., January 18, 2022--Positive results from the HIMALAYA Phase III trial showed a single priming dose of tremelimumab added to IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment.
- Business Wire
IMFINZI® (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer
WILMINGTON, Del., January 18, 2022--Positive results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy alone as a 1st-line treatment for patients with advanced biliary tract cancer (BTC).
